BMO Shifts To Neutral Stance On Hormel, Cites Valuation, Trade Concerns
Hormel Foods Corp (NYSE: HRL) has limited near-term upside, according to BMO Capital Markets.
The Analyst
Analyst Kenneth Zaslow downgraded Hormel Foods from Outperform to Market Perform and increased the price target from $38 to $44.
The Thesis
Hormel's outperformance and valuation expansion prompted the downgrade, rather than a shift in BMO's long-term view concerning the company or its underlying fundamentals, Zaslow said in the downgrade note. (See his track record here.)
Hormel is likely to return to operating profit in 2019 thanks to improving turkey numbers, the analyst said.
"Our case for aggressively investing in HRL is less persuasive at current valuations and trade uncertainties," Zaslow said.
The stock has outperformed the S&P 500 by more than 1,700 basis points over the past 12 months, he said, adding that the valuation reflects a significant premium to the equity's historical average.
Relative to the packaged food peer group's 13 times multiple, Hormel shares trade at 15.8 times BMO's FY2019 EV/EBITDA estimates for the company.
The premium to peers is justified due to Hormel's "strong execution, above-average portfolio growth and significant market shares in niche categories create a stronger growth profile with lower earnings variability than its peers," Zaslow said.
BMO's 2019 estimates for Hormel are premised on 5-percent EBITDA growth, facilitated by a 20-percent-plus improvement in turkey, a mix shift in refrigerated goods, a 5-to-10-cent accretion from its recent acquisition, lower input costs, cost savings initiatives and strong pork cutout margins.
The Price Action
Hormel shares have gained about 18 percent year-to-date. The stock was down 1.58 percent at $41.24 at the time of publication Monday.
Related Links:
Jefferies Initiates Coverage Of Major Food Players
Credit Suisse's Winners And Losers In The Food Space
Latest Ratings for HRL
Sep 2018 | BMO Capital | Downgrades | Outperform | Market Perform |
Aug 2018 | Barclays | Downgrades | Overweight | Equal-Weight |
Aug 2018 | Buckingham | Maintains | Neutral | Neutral |
View More Analyst Ratings for HRL
View the Latest Analyst Ratings
See more from Benzinga
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Pacira Shares Look Expensive, Stifel Says In Bearish Initiation
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
